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ABSTRACT
Transcatheter aortic valve implantation (TAVI) is a proven 
treatment for life- threatening aortic valve disease, 
predominantly severe aortic stenosis. However, even 
among developed nations, access to TAVI is not uniform. 
The Valve for Life initiative was launched by the European 
Association of Percutaneous Cardiovascular Interventions 
in 2015 with the objective of improving access to 
transcatheter valve interventions across Europe. The UK 
has been identified as a country with low penetration of 
these procedures and has been selected as the fourth 
nation to be included in the initiative. Specifically, the 
number of TAVI procedures carried out in the UK is 
significantly lower than almost all other European nations. 
Furthermore, there is substantial geographical inequity 
in access to TAVI within the UK. As a consequence of 
this underprovision, waiting times for TAVI are long, and 
mortality among those waiting intervention is significant. 
This article reviews these issues, reports new data on 
access to TAVI in the UK and presents the proposals of the 
UK Valve for Life team to address the current problems in 
association with the British Cardiovascular Intervention 
Society.
INTRODUCTION
The Valve for Life initiative was launched by 
the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI) in 
2015 with the objective of improving access 
to transcatheter valve interventions across 
Europe. The approach has been founded on 
four tenets: to raise awareness of the impor-
tance of valvular heart disease in the general 
population, to facilitate access to transcath-
eter heart valve interventions, to raise educa-
tional standards and thereby reduce obstacles 
to therapy implementation and to diminish 
age and gender discrimination in the access 
to care.1
The objectives of Valve for Life are ambitious, 
requiring improved delivery of transcatheter 
valve interventions within countries as well 
as reducing disparities between them. Coun-
tries selected are those where penetration of 
transcatheter procedures is low; the Valve for 
Life programme is an opportunity to iden-
tify the obstacles that contribute to this and 
engage change. The inaugural Valve for Life 
initiative was launched in Poland and quickly 
made its mark, with the Polish Ministry of 
Health allocating sufficient funds to increase 
the number of transcatheter valve interven-
tions by 20% for the following year.1 Subse-
quent projects in France and Portugal have 
been well received and successful, and the 
UK has been selected as the fourth country 
to be included in the programme. This 
article, focussing exclusively on transcatheter 
aortic valve implantation (TAVI) as the domi-
nant established transcatheter valve therapy 
(TVT), will outline the nature and scale of 
the problem to be tackled in the UK and will 
describe the proposals of the UK Valve for 
Life team to overcome them.
THE UK VALVE FOR LIFE INITIATIVE
The UK Valve for Life initiative has been 
awarded a substantial grant (Appendix 1) 
by the EAPCI with the aim of supporting a 
comprehensive national project to improve 
delivery of TVTs. This grant has been collec-
tively provided by all major transcatheter 
heart valve manufacturers. The initiative is 
spearheaded by a team of eight clinicians 
from different regions of the UK, each with 
an interest and expertise in valvular heart 
disease and working under the umbrella 
of the British Cardiovascular Intervention 
Society (BCIS). In order to increase patient 
access to transcatheter heart therapies, the 
team will lobby NHS England and the Depart-
ment of Health and Social Care in order to 
promote the agenda of increasing provision 
for the management of valvular heart disease.
The team will also interact directly with 
trusts, through designated ‘local champions’ 
who work at regional heart valve centres, 
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with the intention of implementing pathways designed 
to improve service provision. Finally, there will be an 
emphasis placed on increasing awareness among clini-
cians and the public through educational programmes 
and media activities.
THE UK DEFICIT IN TAVI
National underprovision
The number of TAVI procedures performed in the UK 
per head of population is currently significantly lower 
than almost all other European nations (figure 1A). 
In 2019, for example, 78 TAVI procedures per million 
population (pmp) were undertaken, compared with a 
European average of 141 pmp and as high as 292 pmp 
in Germany.
Multiple factors are likely to explain the low relative 
number of TAVI procedures carried out in the UK. First, 
the number of TAVI centres in the UK is small, with only 
0.53 centres per million population, around one- third the 
average in Western Europe (figure 1B). Second, capacity 
in existing centres is limited. In a survey conducted of UK 
TAVI centres, inadequate cardiac catheterisation labo-
ratory capacity and bed numbers were most frequently 
identified as the factors limiting the expansion of TAVI 
numbers (stated to be the main factor or a significant 
factor in 74% and 56% of respondents, respectively). 
Access to cardiac CT was also a common problem, with 
45% of respondents citing this as the main factor or a 
significant factor. Finally, limitations on TAVI numbers 
imposed by commissioners also impact on procedure 
volume in many centres; 35% of respondents identified 
this as the main factor or a significant factor preventing 
expansion of TAVI numbers.
Inequity of access within the UK
In addition to underprovision of TAVI in the UK as 
a whole, there is also substantial geographic inequity 
within the NHS. We analysed the rate of TAVI procedures 
per million according to NHS England Clinical Commis-
sioning Group, NHS Wales Health Board and nationally 
in Scotland and Northern Ireland, using data obtained 
from the National Institute for Cardiovascular Outcomes 
Research (figure 2). This analysis shows an 11- fold vari-
ation in TAVI numbers pmp, ranging from 194 to 17.2. 
In total, 39 areas had fewer than 50 TAVIs pmp, and 48 
over 100, a remarkable disparity. Although a degree of 
geographical variation is inevitable and may be driven 
by differences in the local population, in particular, 
with respect to age, such profound regional differences 
cannot be explained solely by demographics.
TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)
Aortic stenosis (AS) is one of the most common forms of 
valvular heart disease, with approximately 5% of adults 
over the age of 65 affected,2 and is invariably progres-
sive. Once stenosis is severe, symptoms of breathlessness, 
angina and syncope follow. Quality of life (QOL) declines 
and the prognosis is poor, with 50% of patients dead 
within 2 years of symptom onset and a mortality rate at 5 
years of 97%.3 As illustrated in figure 3, this is worse than 
the mortality associated with metastatic breast, colorectal, 
prostate or ovarian cancers and is comparable to meta-
static lung cancer.4
Until the early 2000s, surgical aortic valve replacement 
(SAVR) was the only treatment for severe, symptomatic 
AS that had been demonstrated to improve mortality.5 
Figure 1 (A) Comparison of number of TAVI procedures carried out per million population in different European countries. (B) 
Comparison of number of TAVI centres per million population in different European countries. TAVI, transcatheter aortic valve 
implantation.
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However, open heart surgery is a major procedure with 
significant inherent risks, particularly in an elderly patient 
cohort. As such, a substantial proportion of patients 
(30%–40%) with severe, symptomatic AS is turned down 
for SAVR due to advanced age and/or comorbidity.6 
TAVI is a minimally invasive procedure that allows tran-
scatheter deployment of a replacement valve using arte-
rial access and avoiding any major surgical intervention. 
The first TAVI was carried out in 2002 and the subse-
quent adoption and expansion of TAVI within routine 
clinical practice have revolutionised the treatment of 
severe, symptomatic AS. The success of TAVI has been 
built on evidence from landmark studies; the PARTNER 
(Placement of AoRtic TraNscathetER Valve) 1B trial 
demonstrated that TAVI was associated with a 50% reduc-
tion in mortality compared with medical therapy among 
Figure 2 An illustrative representation of the geographical variation in TAVI procedures carried out in the UK in 2019. TAVI, 
transcatheter aortic valve implantation.
Figure 3 A comparison of the prognosis of untreated severe AS to the most common metastatic cancers in the UK. Figures 
for cancer survival obtained from the Office of National Statistics (ONS). AS, aortic stenosis; Ca, carcinoma.
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inoperable patients with severe, symptomatic AS,7 while 
PARTNER 1A showed TAVI to be noninferior to SAVR 
in high surgical risk patients.8 9 Subsequent to this, use 
of TAVI has expanded into lower risk patient cohorts, 
and a number of studies have demonstrated outcomes 
following TAVI to be at least equivalent to SAVR in inter-
mediate and low surgical- risk patients.10–14
In addition to excellent clinical outcomes in compar-
ison to SAVR, TAVI is much less invasive, with a signifi-
cantly reduced hospital stay, more rapid recovery and far 
less consumption of hospital resources. TAVI is percuta-
neous and performed under local anaesthetic in >95% 
of patients in the UK. In the UK TAVI randomised trial, 
median hospital stay was 3 days for TAVI compared 
with 8 days for SAVR, median intensive care unit (ICU) 
bed day use was zero in the TAVI group, and QOL was 
improved after only 2 weeks in comparison to 6 months 
after SAVR.14 Minimisation of hospital stay, avoidance of 
ventilation and use of ICU, and more rapid recovery with 
TAVI in contrast to SAVR may be of particular merit in 
the era of the COVID-19 pandemic, when the premium 
placed on preserving healthcare resources and mini-
mising hospital contact is even more profound.
The impact of underprovision of TAVI in the UK
Waiting lists
Across the NHS, demand for TAVI far outstrips capacity, 
and as a result, patients with this debilitating and life- 
threatening condition face long waits for treatment. We 
performed an analysis of waiting times for TAVI in the 
NHS in 2019. Among 23 centres from which data were 
obtained, the median waiting time from referral to TAVI 
was 141 days—over 20 weeks (table 1). Geographical 
inequity in waiting times is also evident, with the median 
time from referral to TAVI varying from 9 weeks to 35 
weeks. Furthermore, these times do not take into account 
the delay from the onset of symptoms to assessment by 
a general practicioner, followed by referral to a local 
hospital, and then eventual referral to the TAVI centre.
Mortality
Since the median survival of severe symptomatic AS is 
worse than almost any metastatic cancer, it is not unex-
pected that inadequate capacity and long waiting lists 
translate to mortality. A study published in 2014 showed 
that a delay to TAVI of 6 months led to almost a quarter 
of patients (23.3%) dying on the waiting list.15 In our 
survey of 23 UK TAVI centres, there were 299 deaths 
among patients awaiting TAVI in 2019. If extended to all 
35 centres performing TAVI in the UK, this would trans-
late to over 500 avoidable deaths annually. Again, there 
was significant geographical variation, with the number 
of deaths per centre for patients awaiting TAVI ranging 
from 1 to 40.
Hospitalisation
As well as death, a long wait for TAVI often leads to clin-
ical deterioration and acute hospital admission. In our 
analysis from 23 UK TAVI centres, 22% of TAVI proce-
dures were in hospitalised patients. The median hospital 
stay was 33 days among in- patients, compared with 3 days 
for those treated from home. A focused analysis in one 
large centre revealed that 39% of urgent in- patient proce-
dures were in subjects who had already been accepted for 
TAVI and were on a waiting list but had decompensated. 
It is clear, therefore, that the long waits for TAVI seen in 
the NHS not only result in unnecessary deaths but also in 
the avoidable consumption of hospital beds.
Valve for Life TAVI proposals
Introduction of a fast-track TAVI pathway
There is currently no specific treatment time target 
for TAVI in the UK. NHS policy mandates a maximum 
waiting time for non- urgent, consultant- led treatments of 
18 weeks and this is used as a target from time of referral 
to treatment in the case of SAVR. However, this is not 
consistently applied to TAVI, and as our survey shows, is 
not being achieved across UK centres; fewer than half of 
the 23 centres which provided data reported a median 
time from referral to TAVI of ≤18 weeks (11/23; 47.8%).
Since severe symptomatic AS has a prognosis similar to 
or worse than metastatic cancer, Valve for Life proposes 
that an analogous fast- track pathway template used for 
the investigation and treatment of suspected cancer is 
applied to the management of AS, whether by TAVI or 
SAVR (figure 4). The cancer pathway targets are 14 days 
from referral to being seen in a specialist clinic, 31 days 
from decision to treat to definitive treatment and 62 days 
in total from time of referral to start of treatment. We 
propose that centres offer a single common pathway for 
AS, incorporating surgical or TAVI clinic appointment 
within 2 weeks. Following outpatient assessment, patients 
would be discussed at the heart valve multidisciplinary 
team (MDT) meeting and undergo valve intervention, if 
Table 1 Data from a survey of UK TAVI centres demonstrating the average waiting time from referral to TAVI during 2019
Median wait (days)
IQR
(days) Mean wait (days)
SD
(days)
Referral to clinic appointment 45 39–57 54.0 23.1
Clinic appointment to discussion at MDT meeting 45 28–59 59.0 31.9
Discussion at MDT meeting to TAVI 37 31–71.5 66 48.3
Overall time from referral to TAVI 141 115–165 155 50.4
IQR, interquartile range; MDT, multidisciplinary team; TAVI, transcatheter aortic valve implantation.
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appropriate, with a target of 8 weeks in total from referral 
to treatment.
The Valve for Life fast- track pathway for TAVI is consis-
tent with proposals from the NHS England Specialised 
Cardiac Improvement Programme (SCIP). SCIP is yet 
to report its final recommendations but is proposing 
a similar accelerated pathway for AS, which is likely to 
include a recommendation for a maximum 18- week wait 
for treatment of severe symptomatic AS from the time of 
diagnosis. If implemented, this would address the delays 
patients often face before referral to the Valve centre 
is made. The 8- week target from referral to treatment 
proposed by Valve for Life would fit into this overall 
18- week pathway.
Delivering a fast-track pathway
The 8- week treatment target will be a mandatory require-
ment against which individual providers are measured. 
Such a centrally mandated NHS pathway will require 
hospitals to prioritise allocation of resources to valve 
services in order to meet the targets. Nevertheless, we 
recognise that delivering definitive treatment by TAVI or 
SAVR within 8 weeks of referral would represent a major 
challenge for centres across the NHS. Valve for Life will 
propose a number of measures to help meet this ambi-
tious but essential target.
Single referral point
All referrals for treatment of AS would be received 
through a single referral point. The Valve team would 
assign each patient a priority rating based on clinical 
urgency, triage patients to SAVR, TAVI or a joint clinic as 
appropriate, and ensure all required investigations had 
been performed or were planned.
Streamlining referral and investigation
Invasive coronary angiography would no longer be 
mandated prior to referral, with CT coronary angiography 
used both for the exclusion of significant coronary artery 
disease and for assessment of vascular access and aortic 
valve anatomy prior to TAVI or SAVR. In cases where inva-
sive angiography was felt to be necessary, this would be 
arranged at the point of triage. CT would be performed 
in the referring centre where possible, or otherwise at 
a one- stop visit to coincide with the outpatient appoint-
ment at the specialist Valve centre. All other assessments, 
including consultant review, appraisal by the valve nurse 
specialist including frailty assessment, ECG and transtho-
racic echocardiography, would be performed at the one- 
stop clinic.
Maximising capacity in existing TAVI centres
Advances in technology, as well as refinement of tech-
nique, have led to streamlining of the TAVI procedure, 
enabling a minimalist TAVI approach. This allows a 
shorter procedure time, and, hence, more patients to 
be treated on a list as well as more rapid recovery and 
reduced hospital stay. However, adoption of minimalist 
TAVI in the UK is highly variable. While many centres 
now perform four or more fully percutaneous procedures 
per day without general anaesthesia, with postoperative 
care in a level 1 bed, and with discharge 1–2 days post-
procedure, this is by no means universal. Valve for Life 
proposes a series of benchmarking standards, described 
in table 2, that would be audited nationally and would 
require all centres to deliver the TAVI procedural pathway 
as efficiently as possible. The Valve for Life team will work 
with the identified local champions in each heart valve 
Figure 4 Proposal for a new fast- track TAVI pathway showing valve for life targets as well as the NHS England Specialised 
Cardiac Improvement Programme (SCIP) 18 week target from diagnosis to treatment. AS, aortic stenosis; MDT, multidisciplinary 
team; SAVR, surgical aortic valve replacement; SCIP, Specialised Cardiac Improvement Programme; TAVI, transcatheter aortic 
valve intervention.
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centre to streamline the local TAVI service, in order to 
optimise capacity and enable the fast- track pathway to be 
delivered.
Achieving a fast- track TAVI pathway may also require 
an increase in capacity, particularly, in those areas where 
procedural numbers are low and waiting lists long. The 
data obtained and described in detail above would be 
used to target those TAVI centres where these prob-
lems are most marked, and where increasing as well as 
optimising capacity may be needed. This aspect of our 
proposals is currently being formulated in a combined 
initiative between BCIS and Valve for Life and will be 
presented in detail in a formal report. It is important 
to recognise that increasing the number of TAVIs that 
centres can undertake will also require greater capacity 
for pre- TAVI workup. Specifically, availability of pre- TAVI 
clinic appointments, CT scans and MDT meetings would 
need to be increased. Such measures will require a collab-
orative effort between departments as well as meaningful 
financial investment.
Expanding the number of UK TAVI centres
The number of TAVI centres in the UK is the lowest in 
Europe by population (figure 1B). The current arrange-
ment in the UK is that only cardiac surgical centres offer 
TAVI, leading to a hub- and- spoke model, whereby district 
general hospitals refer patients to surgical centres. At 
present, every cardiac surgical centre in the UK provides 
a TAVI service. Therefore, increasing the number of 
TAVI centres would require expansion into hospitals 
without on- site cardiac surgery. Such a strategy may prove 
challenging due to concern that a lack of on- site surgical 
back up in the event of a complication could compromise 
procedural safety. Furthermore, the absence of surgical 
colleagues may pose challenges for the MDT approach 
that underpins TAVI. However, it is worth noting that 
existing data show that the need for emergency surgery 
is low, and that the number of patients saved as a result 
is very small. A study published in 2018 including 27 760 
patients who underwent TAVI between 2013 and 2016 
examined the incidence and outcomes of emergency 
cardiac surgery following complications related to trans-
femoral TAVI.16 The authors found that only 0.76% of 
patients who underwent TAVI required emergency cardiac 
surgery, and that this was associated with a high mortality 
as 78% of these patients died within 12 months. When 
looking at the study population as a whole, only 0.16% of 
patients had emergency surgery and then survived for 12 
months. Applying this to the UK TAVI population, if we 
use the number of TAVIs performed between 2018 and 
2019, the provision of emergency cardiac surgery would 
have allowed nine patients to survive 1 year or more; 
significantly fewer than died while waiting for TAVI.
It is acknowledged that expansion into smaller nonsur-
gical centres with potentially lower procedural volume 
may compromise patient outcomes. Data from the US 
TVT registry of almost 100 000 patients who underwent 
TAVI at over 500 sites showed reduced mortality in 
the highest volume centres (86–371 TAVI/year) when 
compared with the lowest volume centres (5–36 TAVI/
year).17 However, the difference in 30- day mortality 
(2.66% vs 3.19%) was small, particularly when set in the 
context of the 2%–3% mortality per month for patients 
on a TAVI waiting list. Expansion in centre numbers may, 
therefore, have a significant net benefit even if accom-
panied by a small but measurable increase in procedural 
mortality.
Clearly, developing TAVI programmes at nonsurgical 
centres would require careful planning. Robust defi-
nitions of the necessary processes and services for such 
programmes to be run safely would be required. Close 
collaboration with the neighbouring surgical TAVI centre 
would be essential: cardiac surgical involvement in the 
MDT process would be a prerequisite; prospective TAVI 
operators would need to be trained and mentored; 
careful collaborative patient selection, with referral of 
complex cases to the surgical centre, would be required 
Table 2 Proposed valve for life benchmarking standards for TAVI
Valve for life benchmarking standards for TAVI
1 Use of sedation with local anaesthesia in ≥95% of cases.
2 Use of percutaneous approach in ≥95% of cases.
3 Use of trans- femoral access in ≥90% of cases.
4 Use of radial artery as second access site in ≥90% of cases.
5 Minimalist approach to temporary pacing: pace on the LV wire (no TPW) in ≥90% of cases.
6 Avoidance of any additional invasive lines (eg, CVP, arterial lines, urinary catheterisation) wherever possible.
7 Standard trans- femoral TAVI list of four or more cases per day.
8 Same day admission in ≥50% elective patients.
9 Use of level 1 beds only in ≥90% of elective cases.
10 Discharge of ≥30% of elective patients within 1 day of procedure.
11 Discharge of ≥75% of elective patients within 2 days of procedure.
CVP, central venous pressure; LV, left ventricle; TAVI, transcatheter aortic valve implantation; TPW, temporary pacing wire.
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and provision for transfer for emergency cardiac surgery 
in the rare event of catastrophic procedural complica-
tions would need to be in place.
At present, we believe that optimisation and maximisa-
tion of capacity in existing surgical centres should be the 
priority. Valve for Life plans are to focus on delivery of 
the fast- track pathway and expansion of TAVI numbers in 
the UK by supporting growth in existing surgical centres, 
with particular attention to those centres in areas where 
access to TAVI is most constrained. However, if this 
strategy proves ineffective, we believe that expansion 
into new centres is an option that should be considered, 
particularly in areas where access to TAVI continues to be 
limited. Under such circumstances, Valve for Life would 
plan to work with BCIS to define the service specification 
for a TAVI centre without on- site cardiac surgery, so that 
this option may be explored.
CONCLUSIONS
Transcatheter valve interventions have revolutionised 
the management of valvular disease, providing evidence- 
based treatments for patients with no other definitive 
therapy options as well as offering a minimally invasive 
alternative to traditional surgery. TAVI is a proven and 
highly effective treatment for a disease whose impact on 
both patients and healthcare systems is profound. Regret-
tably, the UK lags behind the majority of European coun-
tries with regard to TAVI, and we have shown that this 
underprovision is associated with inequity of access to 
treatment, long waiting lists, avoidable and wasteful use 
of hospital resources and significant numbers of deaths 
among untreated patients.
The Valve for Life programme offers a hugely valuable 
opportunity to address these issues. We believe that the 
proposed measures have the potential to substantially 
improve the care given to patients across the NHS who 
are suffering from AS. The objectives of the Valve for 
Life programme are ambitious, but we hope that the UK 
experience will be as successful as previous initiatives and 
leave a lasting legacy that will benefit patients for years 
to come.
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